Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELA-PAED: Intravenous melatonin for preventing emergence agitation and delirium in children
2024-517592-20-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Emergence agitation (EA) comparing Intravenous melatonin with Placebo (intravenous sodium chloride) (2 arms). Primary endpoint: Emergence agitation. Planned start Jan 2025; status: authorised.
02
Drugs
melatonin
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on 2024-517592-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517592-20-00.